CN103242305A - 一种阿齐沙坦的制备方法 - Google Patents
一种阿齐沙坦的制备方法 Download PDFInfo
- Publication number
- CN103242305A CN103242305A CN2013101864637A CN201310186463A CN103242305A CN 103242305 A CN103242305 A CN 103242305A CN 2013101864637 A CN2013101864637 A CN 2013101864637A CN 201310186463 A CN201310186463 A CN 201310186463A CN 103242305 A CN103242305 A CN 103242305A
- Authority
- CN
- China
- Prior art keywords
- preparation
- compound
- reaction
- qishatan
- azilsartan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- 239000005485 Azilsartan Substances 0.000 title abstract 4
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 title abstract 4
- 229960002731 azilsartan Drugs 0.000 title abstract 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 50
- 239000003513 alkali Substances 0.000 claims abstract description 9
- WTDHULULXKLSOZ-UHFFFAOYSA-N hydroxylamine hydrochloride Substances Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940125904 compound 1 Drugs 0.000 claims abstract description 6
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 36
- 229940126214 compound 3 Drugs 0.000 claims description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 229940125782 compound 2 Drugs 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims description 3
- 229940125898 compound 5 Drugs 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000007810 chemical reaction solvent Substances 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 8
- 239000012535 impurity Substances 0.000 abstract description 6
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000007062 hydrolysis Effects 0.000 abstract description 4
- 230000010933 acylation Effects 0.000 abstract description 2
- 238000005917 acylation reaction Methods 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 230000035484 reaction time Effects 0.000 abstract description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 abstract 1
- WCYJQVALWQMJGE-UHFFFAOYSA-M hydroxylammonium chloride Chemical compound [Cl-].O[NH3+] WCYJQVALWQMJGE-UHFFFAOYSA-M 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 238000013019 agitation Methods 0.000 description 13
- 238000000967 suction filtration Methods 0.000 description 12
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 8
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 8
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 239000005480 Olmesartan Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 2
- 229960004349 candesartan cilexetil Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 229960005117 olmesartan Drugs 0.000 description 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- DEKJJZVBGQUKPQ-UHFFFAOYSA-N CCOc1nc2cccc(C(O)=O)c2[n]1Cc(cc1)ccc1-c1ccccc1C(N)=O Chemical compound CCOc1nc2cccc(C(O)=O)c2[n]1Cc(cc1)ccc1-c1ccccc1C(N)=O DEKJJZVBGQUKPQ-UHFFFAOYSA-N 0.000 description 1
- OQJREYQHKLULTR-UHFFFAOYSA-N CCOc1nc2cccc(C(OC)=O)c2[n]1Cc(cc1)ccc1-c1ccccc1/C(/N)=N/O Chemical compound CCOc1nc2cccc(C(OC)=O)c2[n]1Cc(cc1)ccc1-c1ccccc1/C(/N)=N/O OQJREYQHKLULTR-UHFFFAOYSA-N 0.000 description 1
- 0 CCOc1nc2cccc(C(OC)=O)c2[n]1Cc(cc1)ccc1-c1ccccc1C(N)=NOC(O*)=O Chemical compound CCOc1nc2cccc(C(OC)=O)c2[n]1Cc(cc1)ccc1-c1ccccc1C(N)=NOC(O*)=O 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 230000006179 O-acylation Effects 0.000 description 1
- LLINNBQUGIKCPM-UHFFFAOYSA-N OC(c(cccc1N2)c1N(Cc(cc1)ccc1-c(cccc1)c1C(NO1)=NC1=O)C2=O)=O Chemical compound OC(c(cccc1N2)c1N(Cc(cc1)ccc1-c(cccc1)c1C(NO1)=NC1=O)C2=O)=O LLINNBQUGIKCPM-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960000519 losartan potassium Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- -1 oxadiazole compound Chemical class 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- UJJDEOLXODWCGK-UHFFFAOYSA-N tert-butyl carbonochloridate Chemical compound CC(C)(C)OC(Cl)=O UJJDEOLXODWCGK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310186463.7A CN103242305B (zh) | 2013-05-11 | 2013-05-11 | 一种阿齐沙坦的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310186463.7A CN103242305B (zh) | 2013-05-11 | 2013-05-11 | 一种阿齐沙坦的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103242305A true CN103242305A (zh) | 2013-08-14 |
CN103242305B CN103242305B (zh) | 2018-02-27 |
Family
ID=48922210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310186463.7A Active CN103242305B (zh) | 2013-05-11 | 2013-05-11 | 一种阿齐沙坦的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103242305B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103588764A (zh) * | 2013-11-11 | 2014-02-19 | 浙江永宁药业股份有限公司 | 阿齐沙坦酯或其盐的合成方法及其中间体 |
CN103588765A (zh) * | 2013-11-11 | 2014-02-19 | 浙江永宁药业股份有限公司 | 阿齐沙坦酯或其盐的合成方法及其中间体和中间体的合成方法 |
CN103601723A (zh) * | 2013-11-19 | 2014-02-26 | 合肥远志医药科技开发有限公司 | 一种阿齐沙坦的工业化生产方法 |
CN104262334A (zh) * | 2014-09-16 | 2015-01-07 | 常州大学 | 一种阿奇沙坦晶体及其制备方法 |
WO2016147120A1 (en) * | 2015-03-18 | 2016-09-22 | Smilax Laboratories Limited | An improved process for the preparation of substantially pure azilsartan |
CN108752328A (zh) * | 2018-07-27 | 2018-11-06 | 常州大学 | 一种简便合成阿齐沙坦的方法 |
CN108947993A (zh) * | 2018-07-27 | 2018-12-07 | 常州大学 | 一种水相中绿色高效合成阿齐沙坦的方法 |
CN110386928A (zh) * | 2019-08-26 | 2019-10-29 | 海南皇隆制药股份有限公司 | 一种阿齐沙坦合成工艺 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1067890A (zh) * | 1991-06-27 | 1993-01-13 | 武田药品工业株式会社 | 杂环化合物,其制备及应用 |
JP2001097964A (ja) * | 1999-09-27 | 2001-04-10 | Fuji Photo Film Co Ltd | オキサジアゾロン化合物及びその製造方法、並びに、アミドキシム化合物 |
CN101534832A (zh) * | 2006-09-20 | 2009-09-16 | 波托拉医药品公司 | 作为血小板adp受体抑制剂的被取代的含氮杂环类化合物 |
CN102731491A (zh) * | 2012-07-04 | 2012-10-17 | 北京科莱博医药开发有限责任公司 | 一种阿齐沙坦中间体的制备方法 |
-
2013
- 2013-05-11 CN CN201310186463.7A patent/CN103242305B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1067890A (zh) * | 1991-06-27 | 1993-01-13 | 武田药品工业株式会社 | 杂环化合物,其制备及应用 |
JP2001097964A (ja) * | 1999-09-27 | 2001-04-10 | Fuji Photo Film Co Ltd | オキサジアゾロン化合物及びその製造方法、並びに、アミドキシム化合物 |
CN101534832A (zh) * | 2006-09-20 | 2009-09-16 | 波托拉医药品公司 | 作为血小板adp受体抑制剂的被取代的含氮杂环类化合物 |
CN102731491A (zh) * | 2012-07-04 | 2012-10-17 | 北京科莱博医药开发有限责任公司 | 一种阿齐沙坦中间体的制备方法 |
Non-Patent Citations (1)
Title |
---|
束蓓艳,等: "阿奇沙坦的合成", 《中国医药工业杂志》 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103588764A (zh) * | 2013-11-11 | 2014-02-19 | 浙江永宁药业股份有限公司 | 阿齐沙坦酯或其盐的合成方法及其中间体 |
CN103588765A (zh) * | 2013-11-11 | 2014-02-19 | 浙江永宁药业股份有限公司 | 阿齐沙坦酯或其盐的合成方法及其中间体和中间体的合成方法 |
CN103588765B (zh) * | 2013-11-11 | 2016-01-13 | 浙江永宁药业股份有限公司 | 阿齐沙坦酯或其盐的合成方法及其中间体和中间体的合成方法 |
CN103601723A (zh) * | 2013-11-19 | 2014-02-26 | 合肥远志医药科技开发有限公司 | 一种阿齐沙坦的工业化生产方法 |
CN103601723B (zh) * | 2013-11-19 | 2016-04-27 | 合肥远志医药科技开发有限公司 | 一种阿齐沙坦的工业化生产方法 |
CN104262334A (zh) * | 2014-09-16 | 2015-01-07 | 常州大学 | 一种阿奇沙坦晶体及其制备方法 |
WO2016147120A1 (en) * | 2015-03-18 | 2016-09-22 | Smilax Laboratories Limited | An improved process for the preparation of substantially pure azilsartan |
CN108752328A (zh) * | 2018-07-27 | 2018-11-06 | 常州大学 | 一种简便合成阿齐沙坦的方法 |
CN108947993A (zh) * | 2018-07-27 | 2018-12-07 | 常州大学 | 一种水相中绿色高效合成阿齐沙坦的方法 |
CN110386928A (zh) * | 2019-08-26 | 2019-10-29 | 海南皇隆制药股份有限公司 | 一种阿齐沙坦合成工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN103242305B (zh) | 2018-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103242305A (zh) | 一种阿齐沙坦的制备方法 | |
CN107365275B (zh) | 高纯度的赛乐西帕 | |
CN114031543A (zh) | 一种帕罗韦德中间体的制备方法 | |
CN103601723B (zh) | 一种阿齐沙坦的工业化生产方法 | |
CN109912624A (zh) | 一种巴洛沙韦酯关键母核中间体的合成方法 | |
US20230045135A1 (en) | Tedizolid intermediate and efficient preparation method thereof | |
CN114478690B (zh) | 一种6,6-二甲基-3-氮杂双环[3.1.0]己烷衍生物的制备方法 | |
CN103664922A (zh) | 新晶型阿齐沙坦及其制备方法 | |
CN103265482A (zh) | 博舒替尼的制备方法 | |
CN108912030B (zh) | 一种艾瑞昔布的合成方法 | |
CN102060780A (zh) | 2-(n-取代)-氨基苯并咪唑衍生物的制备方法 | |
CN105315256A (zh) | 一种适合工业化的高纯度琥珀酸曲格列汀的制备方法 | |
CN104974105A (zh) | 一种制备4-(4-氨基苯基)-3-吗啉酮的方法 | |
CN108623602B (zh) | 一种制备和纯化依鲁替尼的方法 | |
EP4140993A1 (en) | Efficient preparation method for tedizolid intermediate, and intermediate | |
TW202330535A (zh) | 一種dpp-iv抑制劑及其關鍵中間體的製備方法 | |
CN105153169A (zh) | 一种盐酸依匹斯汀的合成方法 | |
CN108503586B (zh) | 制备托伐普坦中间体的方法 | |
CN104829533A (zh) | 一种托伐普坦关键中间体的制备方法 | |
CN101225069A (zh) | 一种美罗培南中间体的合成方法 | |
CN104311495B (zh) | 一种nh‑1,2,3‑三氮唑的合成方法 | |
CN103408500B (zh) | 一种血管紧张素ⅱ受体拮抗剂及其关键中间体的制备方法 | |
CN104230909B (zh) | 一种阿齐沙坦的制备方法 | |
CN102491954B (zh) | 利奈唑胺的制备方法 | |
CN105924400A (zh) | 阿齐沙坦杂质a和b的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: DISHA PHARMACEUTICAL INDUSTRY GROUP CORP., LTD. WEIHAI DIZHIYA PHARMACHEM. DEVELOPMENT CO., LTD. Effective date: 20150909 Owner name: DISHA PHARMACEUTICAL INDUSTRY GROUP CORP., LTD. Free format text: FORMER OWNER: WEIHAI DIZHIYA PHARMACEUTICAL CO., LTD. Effective date: 20150909 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150909 Address after: 264200 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Applicant after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 264205 No. 46, Guangzhou Road, Wendeng Economic Development Zone, Shandong, Weihai Applicant before: WEIHAI DIZHIYA PHARMACEUTICAL Co.,Ltd. Applicant before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Applicant before: WEIHAI DIZHIYA PHARMACHEM DEV Co.,Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191107 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Co-patentee after: Dijia Pharmaceutical Group Co.,Ltd. Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 264200 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210730 Address after: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 268, Tianrun Road, Wendeng Economic and Technological Development Zone, Weihai City, Shandong Province, 264200 Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of azilsartan Effective date of registration: 20230426 Granted publication date: 20180227 Pledgee: Weihai Branch of Shanghai Pudong Development Bank Co.,Ltd. Pledgor: Dijia Pharmaceutical Group Co.,Ltd. Registration number: Y2023980039205 |